Pro Medicus Ltd (ASX: PME) experienced a significant downturn on Thursday, with its share price plummeting to a multi-year low. The health imaging technology company saw its stock finish the day down a substantial 24%, settling at $129.00.
What Triggered the Sell-Off?
The sharp decline in Pro Medicus shares followed the release of its half-year financial results. While the company reported record-breaking figures, these results ultimately fell short of investor expectations. In the current market climate, where software stocks are facing scrutiny due to concerns about artificial intelligence (AI) disruption, such an earnings miss has proven particularly damaging.
However, many market analysts believe the extent of the sell-off represents a severe overreaction from investors. One prominent voice urging a different perspective is Morgans, a financial services firm that is encouraging investors to consider acquiring Pro Medicus shares while they are trading at these depressed levels.
Morgans’ Take on Pro Medicus’ Performance
Morgans has reviewed Pro Medicus’ latest results and offered its insights. The firm acknowledges that Pro Medicus delivered a record performance, with both revenue and underlying earnings before interest and tax (EBIT) showing an impressive increase of approximately 30% compared to the same period last year.
Despite this strong growth, the results missed consensus expectations. This shortfall is attributed to higher-than-anticipated staff costs and a smaller-than-expected contribution from the significant Trinity contract.
Morgans believes these factors should not overshadow the company’s longer-term growth trajectory, which they argue has been bolstered by substantial new contract wins.
Key Highlights from Morgans’ Analysis:
- Record Financials: Pro Medicus achieved record revenue and underlying EBIT, growing by around 30% year-on-year.
- EBITDA Miss: The company experienced an EBITDA miss due to increased staff costs and a lower contribution from the Trinity contract than initially projected.
- Strengthened Long-Term Outlook: Over A$280 million in new contracts have been secured, pushing the five-year contracted revenue to approximately A$1.1 billion.
- Market Concerns: Investors remain cautious due to a heavy execution load expected in the second half of the financial year and anticipated cost base increases.
In their assessment, Morgans stated:
“PME delivered record revenue and underlying EBIT up ~30% YoY, yet the result fell short of expectations on operating leverage with a jump in staff costs driving an EBITDA miss as Trinity contributed less than anticipated. The longer-term outlook strengthened with more than A$280m of new contracts signed and five-year contracted revenue now around A$1.1bn, though the market remains wary of a heavy 2H execution load and cost base increase. It is not ideal to deliver a miss in this market, but the reaction feels overcooked and the setup into 2H is far better than the share price implies. Our valuation is reduced to A$275 (from A$290) and we retain our Buy recommendation.”
Reaffirmed Buy Rating and Price Target Adjustment
Following the release of the results, Morgans has reiterated its ‘Buy’ recommendation for Pro Medicus shares. They have also adjusted their price target downwards to A$275.00, from a previous target of A$290.00.
Based on the current share price of $129.00, Morgans’ revised price target suggests a potential for the company’s shares to more than double in value within the next year. This optimistic outlook stems from their belief that the market’s reaction has been disproportionate to the company’s underlying performance and future prospects.
Should You Invest in Pro Medicus?
The recent price action in Pro Medicus shares has certainly presented a notable event for investors. While the company has achieved record results, the market’s response indicates a divergence in sentiment.
For those considering an investment in Pro Medicus, it is important to conduct thorough research and consider various expert opinions. The current market environment, with its focus on technological disruption and evolving economic conditions, necessitates a careful approach to investment decisions.
It’s always advisable to consult with a qualified financial advisor to determine if Pro Medicus, or any other investment, aligns with your personal financial goals and risk tolerance. The potential for significant upside, as suggested by some analysts, must be weighed against the inherent risks associated with the stock market.
